VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Bio-Rad Laboratories, Inc. vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bio-Rad Laboratories, Inc.
BIO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.
View BIO analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 61 / 100 for Bio-Rad Laboratories, Inc.).
- Segment focus: Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: Bio-Rad Laboratories, Inc. has 6 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
Bio-Rad Laboratories, Inc.
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Global
Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories
IVD OEM / installed-base consumables supplier (systems + kits + controls)
59.9%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
Bio-Rad Laboratories, Inc. strengths
Gilead Sciences, Inc. strengths
Segment mix
Bio-Rad Laboratories, Inc. segments
Full profile >Life Science
Competitive
Clinical Diagnostics
Oligopoly
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.